Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920979 | 1.00 | PPARD (0.49) | PPARDPOLBAPEX1PPARGUSP2 | |
| SCHEMBL12159987 | 0.94 | PPARD (0.50) | PPARDPOLBAPEX1PPARGMCHR1 | |
| SCHEMBL12160008 | 0.94 | PPARD (0.50) | PPARDPOLBAPEX1PPARGMCHR1 | |
| SCHEMBL12159967 | 0.94 | PPARD (0.50) | PPARDPOLBAPEX1PPARGTSHR | |
| SCHEMBL12160059 | 0.94 | PPARD (0.50) | PPARDPOLBAPEX1PPARGTSHR | |
| SCHEMBL12160151 | 0.92 | PPARD (0.58) | PPARDPOLBAPEX1PPARGNPC1 | |
| SCHEMBL9921052 | 0.92 | PPARD (0.49) | PPARDPOLBAPEX1PPARGTSHR | |
| SCHEMBL9920907 | 0.92 | PPARD (0.49) | PPARDPOLBAPEX1PPARGTSHR | |
| SCHEMBL9920845 | 0.92 | PPARD (0.52) | PPARDPPARGTSHRNPC1MCHR1 | |
| SCHEMBL12160134 | 0.91 | PPARD (0.48) | PPARDPOLBAPEX1PPARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362016-B2 | Phenyl propionic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1979311-B1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | VTVX HOLDINGS II LLC | 2009-04-09 | — | — | US | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PPARD 2/4885POLB 1427/4885APEX1 4586/4885 |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | PPARD 3/4885POLB 769/4885APEX1 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.